Armata Pharmaceuticals, Inc.·4

Mar 11, 9:14 PM ET

Schlesinger Sarah J. 4

Research Summary

AI-generated summary

Updated

Armata (ARMP) Director Sarah Schlesinger Receives Options Award

What Happened

  • Sarah J. Schlesinger, a director of Armata Pharmaceuticals (ARMP), received a grant of 25,640 derivative shares (stock options) on March 9, 2026. The reported acquisition price is $0.00 (award), so no cash was paid at grant.

Key Details

  • Transaction date: 2026-03-09 (Form 4 filed 2026-03-11; appears timely within the 2-business-day filing window).
  • Transaction type: Grant / Award of derivative securities (code A).
  • Amount: 25,640 stock options; reported acquisition value: $0.00.
  • Vesting: Footnote states the stock options will vest in full on March 9, 2027, subject to continuous service through that date.
  • Shares owned after transaction: Not specified in the provided filing excerpt.
  • Exercise price / other terms: Not listed in the provided excerpt.

Context

  • These are option awards, not open-market purchases or sales. The options vest in one year (per the footnote) and generally must vest before they can be exercised; the filing does not indicate any immediate sale or cashless exercise. Awards to directors are common as compensation and do not by themselves indicate a short-term trading signal.